Key facts
- The Skin Diary’s last known valuation is $6.0M (Dec 2024).
- It has raised $1.2M; the latest was Seed Round ($1.2M) in Dec 2024.
- Notable investors include The University of Manchester.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for The Skin Diary
- ·The full record, as it builds
Funding rounds
No funding rounds for The Skin Diary are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About The Skin Diary
Manufacturer of regenerative skincare products intended to simplify the complex world of anti-ageing skincare science. The company elevates skin ageing science with a bespoke prescription ageing treatment delivered monthly, with dermatology oversight, empowering women and men to embracing the natural ageing process and cultivating a sense of confidence in their own skin.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 10
- Website
- theskindiary.com/
- Ownership
- Privately Held (backing)
The Skin Diary doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in The Skin Diary shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on The Skin Diary in its N-PORT filings yet. We sweep new filings monthly.